C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3019% above fair value
$2.77−0.12 (-4.15%)
Close on Nov 12, 2026Market cap $340.78MP/E –Yield –
C4 Therapeutics total assets
Total assets on the balance sheet at the end of each period.
C4 Therapeutics's total assets was $331.80M at Sep 30, 2026. For fiscal 2025 it was $359.08M, up 2.7% from the year before. The highest annual figure on record is $506.77M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $359.08M | +2.7% |
| FY2024 | Dec 31, 2024 | $349.60M | -7.1% |
| FY2023 | Dec 31, 2023 | $376.45M | -12.6% |
| FY2022 | Dec 31, 2022 | $430.84M | -15.0% |
| FY2021 | Dec 31, 2021 | $506.77M | +26.6% |
| FY2020 | Dec 31, 2020 | $400.14M | +238.4% |
| FY2019 | Dec 31, 2019 | $118.26M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $331.80M | +25.0% |
| Q2 FY2026 | Jun 30, 2026 | $359.40M | +21.2% |
| Q1 FY2026 | Mar 31, 2026 | $328.86M | +2.9% |
| Q4 FY2025 | Dec 31, 2025 | $359.08M | +2.7% |
| Q3 FY2025 | Sep 30, 2025 | $265.49M | -29.4% |
| Q2 FY2025 | Jun 30, 2025 | $296.53M | -22.2% |
| Q1 FY2025 | Mar 31, 2025 | $319.52M | -19.8% |
| Q4 FY2024 | Dec 31, 2024 | $349.60M | -7.1% |
| Q3 FY2024 | Sep 30, 2024 | $376.06M | +12.9% |
| Q2 FY2024 | Jun 30, 2024 | $381.09M | +1.6% |
| Q1 FY2024 | Mar 31, 2024 | $398.37M | +0.6% |
| Q4 FY2023 | Dec 31, 2023 | $376.45M | -12.6% |
| Q3 FY2023 | Sep 30, 2023 | $333.01M | -27.8% |
| Q2 FY2023 | Jun 30, 2023 | $375.01M | -23.9% |
| Q1 FY2023 | Mar 31, 2023 | $396.04M | -23.2% |
| Q4 FY2022 | Dec 31, 2022 | $430.84M | -15.0% |
| Q3 FY2022 | Sep 30, 2022 | $461.44M | -9.1% |
| Q2 FY2022 | Jun 30, 2022 | $492.48M | -6.8% |
| Q1 FY2022 | Mar 31, 2022 | $515.49M | +37.8% |
| Q4 FY2021 | Dec 31, 2021 | $506.77M | +26.6% |
| Q3 FY2021 | Sep 30, 2021 | $507.91M | +121.7% |
| Q2 FY2021 | Jun 30, 2021 | $528.42M | +346.8% |
| Q1 FY2021 | Mar 31, 2021 | $374.01M | – |
| Q4 FY2020 | Dec 31, 2020 | $400.14M | – |
| Q3 FY2020 | Sep 30, 2020 | $229.13M | – |
| Q4 FY2019 | Dec 31, 2019 | $118.26M | – |
See a number that looks wrong?